Novavax appoints Jeffrey Stoddard as Vice President, Medical Affairs

He joins the firm with more than 15 years of vaccine research and development experience and leadership roles

Novavax, a clinical-stage vaccine company focused on the development of recombinant nanoparticle vaccines and adjuvants, has appointed Jeffrey Stoddard as Vice President, Medical Affairs.

Stoddard joins Novavax with more than 15 years of vaccine research and development experience and leadership roles. He was instrumental in the commercial launch of multiple vaccines and biologics including Synagis, FluMist, pandemic flu vaccines, Menveo and Bexsero. He was most recently Vice President, Medical Affairs & Medical Professional Services, at Alkermes, where he led medical affairs, and health economics and outcomes research.

Prior to this, Stoddard held positions of increasing responsibility at Novartis Vaccines, Covance and MedImmune.

You may also like

Manufacturing

Sanofi and Novavax co-commercialise COVID-19 vaccine

The agreement will aim to commercialise Novavax's adjuvanted COVID-19 vaccination globally, as well as develop a COVID-19 and flu combination vaccine
Research & Development

Alternating vaccines trial expands to include two additional vaccines

Volunteers, who will have received either the Oxford-AstraZeneca, or Pfizer vaccine, will be randomly allocated to receive either the same vaccine for their second dose, or a dose of the COVID-19 vaccines produced by Moderna or Novavax
You need to be a subscriber to read this article.
Click here to find out more.
Pharmaceutical

Zika outbreak gives rise to global fears

Zika may not be a new virus but its newly confirmed ability to cause foetal brain abnormalities makes the search for a treatment or a vaccine a high priority. Dr Sarah Houlton looks at the latest initiatives
Research & Development

Novavax vaccine candidate produces immune response against deadly virus

Study by University of Maryland School of Medicine highlights potential effective means for preventing MERS-CoV
Research & Development

Novavax, CPL Biologicals and ICGEB to develop malaria vaccine

Will combine Novavax VLP vaccine technology with CPLB manufacturing and ICGEB research capabilities
Manufacturing

Novavax signs long-term lease on vaccine plant

Will relocate corporate hq to same campus in Gaithersburg
Research & Development

US HHS awards influenza contracts worth US$215m

Novavax and VaxInnate to develop VLP and recombinant influenza vaccines, respectively
Subscribe now